Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

Author： Lamond Nathan WD Skedgel Chris Younis Tallal

ISSN： 1473-7167

Source： Expert Review of Pharmacoeconomics and Outcomes Research, Vol.13, Iss.2, 2013-04, pp. : 243-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Uracil/tegafur improves survival in node-negative breast cancer

Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Partial Lower Axillary Dissection for Patients with Clinically Node-negative Breast Cancer

By Kodama H Mise K Kan N

The Journal of International Medical Research, Vol. 40, Iss. 6, 2012-11 ,pp. : 2336-2345

Field House Publishing

Access to resources Recommend Favorite

A deletion in chromosome 11q may predict the response to anthracycline-based chemotherapy in patients with early node-negative breast cancer

Inpharma, Vol. 1, Iss. 1578, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Prognostic Significance of Thrombocytosis in Node-negative Colon Cancer

By Kandemir EG Mayadagli A Karagoz B Bilgi O Turken O Yaylaci M

The Journal of International Medical Research, Vol. 33, Iss. 2, 2005-03 ,pp. : 228-235

Field House Publishing

Access to resources Recommend Favorite

Cost-effective treatments for colorectal cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 646, 2012-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite